The study, led by Zihang Tong and colleagues at the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, pooled evidence from 96 randomized controlled trials encompassing 18,419 adult participants. The research team searched PubMed, the Cochrane Library, Embase, and Web of Science through October 2025, then used network meta-analysis — a statistical framework that combines both direct comparisons between treatments and indirect comparisons linked through a common control — to rank six digital interventions: digital cognitive behavioral therapy (dCBT), digital mindfulness-based therapy (dMBT), digital brief behavioral therapy (dBBT), circadian rhythm support (CRS), virtual reality (VR), and tele-neurofeedback (NFB). By folding every trial into a single evidence network anchored on a shared control node, the method allows treatments never tested against each other in the same trial to be compared with remarkable statistical efficiency.

The headline finding concerns the Insomnia Severity Index, or ISI, a seven-item questionnaire that scores insomnia symptoms from 0 to 28. Compared with control treatment, dCBT reduced ISI scores by an average of 4.24 points, with a 95 percent confidence interval of −4.83 to −3.65 — an estimate supported by moderate-certainty evidence under the CINeMA framework. That figure is not just statistically significant; it crosses the minimal clinically important difference, the threshold — set at 4 points for the ISI in this analysis — beyond which patients and clinicians should actually notice a change. In other words, dCBT is the only intervention in the network whose effect on the core outcome of insomnia severity was unambiguously meaningful for real patients.

The detailed picture across other outcomes is more nuanced. dCBT also significantly improved PSQI scores (a reduction of 2.28 points), shortened subjective sleep onset latency by about 12.6 minutes, raised subjective sleep efficiency by 7.27 percentage points, and cut subjective wake after sleep onset by roughly 17.2 minutes. Yet none of these secondary effects reached their respective minimal clinically important differences, which the authors defined as, for example, at least a 3-point PSQI change or a 20-minute reduction in latency. Digital mindfulness-based therapy produced a smaller but significant ISI reduction of 2.28 points and shortened objectively measured sleep onset latency by 7.96 minutes, the latter based on moderate-certainty evidence from polysomnography and actigraphy studies. Virtual reality, evaluated through an inconsistency model because of statistical heterogeneity, reduced objectively measured wake after sleep onset by 13.38 minutes — significant, but again below the clinical threshold.

Direct head-to-head comparisons within the network reinforced dCBT’s dominance. It outperformed dMBT on the ISI (by 1.96 points) and on subjective total sleep time (by about 10 minutes), beat VR on the PSQI, and surpassed circadian rhythm support on sleep latency and sleep efficiency measures. Using SUCRA statistics, which express the probability that a treatment ranks best, dCBT topped the charts for the ISI (93.3 percent), the PSQI (95.8 percent), subjective sleep onset latency (95.0 percent), and subjective sleep efficiency (93.0 percent). Three interventions — tele-neurofeedback, digital brief behavioral therapy, and circadian rhythm support — showed no statistically significant benefits over control for any outcome, effectively dropping out of the clinical conversation until better evidence emerges.

The authors went well beyond the headline averages. Subgroup analyses probed whether effects differed by control group type, therapist guidance, treatment duration, and population. Notably, dCBT performed as well as face-to-face CBT where such comparisons existed, held up against active controls rather than only passive waitlists, and worked whether delivered with a therapist in the loop or fully automated — the ISI effect was −4.48 points with guidance versus −4.10 points without, a gap of less than half a point. Treatment duration mattered little for the core outcome: the ISI effect was identical (−4.24 points) whether programs ran eight weeks or longer. Effects were somewhat larger in people with insomnia symptoms who lack a formal diagnosis than in diagnosed patients, suggesting those with less entrenched sleep pathology may respond more readily to structured digital programs.

Sensitivity analyses added important caveats about who benefits. dCBT’s effects proved stable across pregnant women, cancer patients, and people with depression or anxiety, indicating broad applicability. dMBT’s efficacy, by contrast, appeared inflated in pregnant women under certain control designs and weaker in cancer survivors, and its improvement on the PSQI was fragile among depressed patients. VR was the most volatile intervention of all: its estimated effects swung dramatically depending on which small studies were included, leading the authors to urge caution about deploying VR in oncology, acute medical settings, and populations with severe somatic disease.

The study is candid about its limitations, and readers should absorb them. Only two of the 96 trials were judged low risk of bias overall, with 94 showing some concerns — especially around outcome measurement, where participants inevitably know what treatment they are receiving, inflating expectancy effects on subjective questionnaires. Heterogeneity was high for the ISI and PSQI, objective sleep outcomes rested on few trials with small samples, roughly 40 trials had potential industry funding, and the analysis captured only immediate post-treatment results with no follow-up data on whether benefits persist. The treatment taxonomy also followed a Chinese expert consensus rather than international regulatory frameworks, which may limit direct comparability with other classification schemes.

Still, the practical implications are hard to escape. For clinicians building insomnia care pathways, the evidence reasonably supports dCBT as the primary digital option, given its clinically meaningful reduction in insomnia severity. dMBT emerges as a reasonable alternative or adjunct — particularly for patients who prefer mindfulness approaches or struggle to adhere to CBT — even though its benefits did not reach clinical significance thresholds. The absence of patient and public involvement in the analysis, the authors acknowledge, means real-world preferences around acceptability remain underexplored. What the study delivers is something prior reviews could not: a single network in which six different digital therapies, from smartphone-delivered CBT to immersive VR, compete on equal statistical footing to answer the question patients actually ask — which one is best.

The research team, funded by Tianjin science and health programs and registered prospectively on PROSPERO, concludes that future work should prioritize large-scale, high-quality randomized trials with standardized interventions, objective outcome frameworks, and long-term follow-up. Until then, this analysis stands as the most complete map of the digital sleep-therapy landscape — one that confirms the promise of treatment delivered by app, but also warns that statistical significance alone is not the same as a patient sleeping meaningfully better. For the 16.2 percent of adults worldwide reporting clinically significant insomnia, the difference between those two thresholds is exactly the kind of precision that evidence-based medicine is meant to provide.

Subject of Research: Comparative effectiveness of digital therapeutics for improving sleep quality in adults with insomnia

Article Title: The effectiveness of digital therapeutics in improving sleep quality: a systematic review and network meta-analysis

Article References: Tong, Z., Ye, G., Fan, S., Li, Y., Zhang, J., Zhang, H., Chen, Q., Wang, H., Li, H., & Wang, J. (2026). The effectiveness of digital therapeutics in improving sleep quality: a systematic review and network meta-analysis. BMC Medicine, 24(1), Article 526. https://doi.org/10.1186/s12916-026-05129-8

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05129-8

Keywords: digital therapeutics, insomnia, sleep quality, network meta-analysis, digital cognitive behavioral therapy, mindfulness, virtual reality, tele-neurofeedback, circadian rhythm support, randomized controlled trials, PSQI, Insomnia Severity Index

Cognitive behavioral therapy, or CBT, is among the most extensively validated psychological treatments for depression. It works on a straightforward premise: that distorted patterns of thinking and maladaptive behaviors reinforce depressive states, and that systematically identifying and restructuring these patterns can produce lasting improvements in mood and functioning. Traditional CBT is delivered face to face by trained therapists, typically over twelve to twenty sessions. This model, while effective, faces severe scalability problems in a country of 1.4 billion people. China has a dramatically uneven distribution of psychiatric resources, with most specialists concentrated in large urban hospitals, leaving adolescents in smaller cities and rural areas with few realistic pathways to care. Stigma surrounding mental illness compounds the problem, discouraging many families from seeking help even when services are available.

Digital CBT offers a potential solution to this access crisis. Previous studies, largely conducted in Western countries, have confirmed that dCBT delivered through computers or smartphones can alleviate depressive symptoms with effect sizes comparable to face-to-face therapy for mild to moderate cases. The interventions typically use structured modules covering psychoeducation, cognitive restructuring, behavioral activation, and relapse prevention, often supplemented by automated feedback or limited therapist contact. However, the researchers behind CADS-D identified a critical gap: no dCBT program existed that was specifically designed for Chinese adolescents, taking into account their language, cultural context, developmental stage, and the particular stressors shaping their mental health, including intense academic pressure and distinctive family dynamics.

To address this gap, the team developed MOCA, a smartphone-based cognitive behavioral therapy program tailored to Chinese teenagers aged 12 to 18. The CADS-D trial is designed as a single-center, two-arm, open-label randomized controlled trial that will enroll a total of 200 adolescents with depressive symptoms. The study’s design reflects careful attention to both scientific rigor and participant safety. Key exclusion criteria are designed to protect vulnerable young people: adolescents with severe depressive symptoms or suicide risk are not eligible, nor are those with comorbid psychiatric disorders beyond depressive disorders, severe physical illness or disability that would prevent use of the smartphone program, current or recent treatment for depression, or inability to complete follow-up assessments. Screening for eligibility draws on established clinical instruments, including the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children, Present and Lifetime Version, a structured diagnostic interview considered the gold standard for assessing psychiatric conditions in young people.

Once enrolled, participants are randomly assigned to one of two groups. The intervention group receives the six-week dCBT program MOCA, working through its therapeutic modules on their smartphones. The control group receives the regular school mental health curriculum, providing an active comparison that reflects what adolescents would ordinarily encounter. This design allows the researchers to isolate the specific effect of the digital therapy program above and beyond standard psychoeducational content. Assessments are scheduled at three time points: baseline before the intervention begins, immediately after the six-week program concludes, and at a three-month follow-up, twelve weeks after the intervention has ended. This extended follow-up window is crucial, because a therapy that produces short-term gains but fails to sustain them offers limited real-world value.

The trial’s primary outcome is the change in depressive symptom severity from baseline to the post-intervention assessment at week six. Symptom severity is measured using validated clinical scales, including the Children’s Depression Rating Scale-Revised, a clinician-rated instrument, alongside self-report measures such as the Center for Epidemiologic Studies Depression Scale for Children and the 9-item Patient Health Questionnaire. Secondary outcomes, assessed at both the post-intervention and follow-up time points, include feasibility measures and changes from baseline in self-reported depressive symptoms, anxiety symptoms measured with the Generalized Anxiety Disorder 7-item Scale, psychological resilience assessed with the Connor-Davidson Resilience Scale, and quality of life enjoyment and satisfaction captured by the Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire. This battery of measures reflects a modern understanding that successful treatment should improve not just symptom counts but the broader texture of a young person’s daily life.

Statistically, the research team plans to analyze the data using linear mixed-effects models, a flexible framework well suited to repeated-measures trial designs. Mixed-effects models can handle missing data more gracefully than simpler approaches and account for the correlation between repeated measurements taken from the same individual over time. Outcome assessors conduct clinical assessments while remaining masked to group allocation, reducing the risk of assessor bias contaminating the results, even though the open-label design means participants necessarily know which treatment they are receiving. The data management and analysis team operates separately, responsible for database maintenance, data monitoring, and masked statistical analysis, further insulating the scientific conclusions from potential bias.

The trial’s organizational structure follows established standards for clinical research conduct. The First Affiliated Hospital of Chongqing Medical University serves as the coordinating site, with the principal investigator and core research team responsible for study design, trial supervision, safety management, and reporting. Trained research assistants handle participant recruitment, intervention coordination, attendance recording, and follow-up management. Ethics approval was granted by the hospital’s ethics committee, and the study complies with the Declaration of Helsinki, with written informed consent obtained from all participants and at least one of their guardians. The trial was registered with ClinicalTrials.gov on 9 September 2025 under identifier NCT07163013, and the first participant was enrolled in May 2025, with the study currently ongoing. The work is supported by the National Key R&D Program of China, STI2030-Major Projects, the National Natural Science Foundation of China, and the Natural Science Foundation of Chongqing, with the funders having no role in the study’s design, execution, analysis, or the decision to submit results.

The stakes of this research extend well beyond a single trial. If MOCA proves effective and feasible, it could transform the therapeutic landscape for millions of Chinese adolescents experiencing depressive symptoms. A smartphone program costs a fraction of face-to-face therapy to deliver, can reach young people regardless of geography, and offers a degree of privacy that may lower the stigma barrier preventing help-seeking. Digital delivery also allows adolescents to engage with therapeutic content at their own pace and revisit modules as needed, features that some young users find more comfortable than conventional clinical encounters. The researchers emphasize that findings from CADS-D will provide empirical evidence regarding both the efficacy and the feasibility of dCBT among Chinese adolescents, filling a conspicuous void in the literature. Should the results be positive, the path forward would involve broader implementation studies and eventual integration with school-based and primary care mental health services, potentially creating a tiered system in which digital therapy serves as an accessible first line of support. In a world where adolescent mental health services everywhere are stretched thin, the outcome of this Chinese trial will be watched closely by clinicians and policymakers far beyond its borders.

Subject of Research: A randomized controlled trial evaluating smartphone-based digital cognitive behavioral therapy for Chinese adolescents with depressive symptoms.

Article Title: Digital Cognitive Behavioral Therapy for Chinese Adolescents with Depressive Symptoms (CADS-D): protocol for a randomized controlled trial

Article References: Lei, T., Wang, N., Wang, R., He, Y., Liu, X., & Zhou, X. (2026). Digital Cognitive Behavioral Therapy for Chinese Adolescents with Depressive Symptoms (CADS-D): protocol for a randomized controlled trial. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08657-y

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08657-y

Keywords: digital cognitive behavioral therapy, adolescent depression, randomized controlled trial, mental health, China, smartphone intervention, CBT, depressive symptoms, psychiatry, MOCA program, youth mental health, BMC Psychiatry